Results of the observational study EVA PLUS: Use of combined oral contraceptives with f olate in real clinical practice in Russia

Khamoshina M.B.

Medical Institute, Peoples’ Friendship University of Russia, Moscow, Russia
Objective. To estimate the level of satisfaction with the use of the contraceptive Yaz® Plus by women and physicians in real clinical practice.
Subjects and methods. A prospective, multicenter observational study was conducted in 1484 women over 18 years of the age, who used Yaz® Plus for contraception.
Results. The use of the contraceptive Yaz® Plus was accompanied by a high satisfaction by both women (4.7 points out of 5) and physicians (4.8 points out of 5). Medication adherence during a year of therapy was 88.9%. The total observational time was 1406.69 women-years of medication use. The incidence of adverse events (AEs) was one event per 8.85 women-years of use. During the study, 159 AEs were recorded in 113 (7.61%) women. Most of the AEs were classified as mild (n = 131) and moderate (n = 28) AEs in 97 (6.54%) and 23 (1.55%) women, respectively.
Conclusion. The use of Yaz® Plus prescribed for contraception in real clinical practice was accompanied by a high level of satisfaction. The choice of physicians who have recommended Yaz® Plus determines the contraceptive effectiveness of the medication and the possibility of everyday compensation for the optimal daily dose of folates.


Yaz® Plus
real clinical practice


  1. Архипова М.П., Хамошина М.Б. Репродуктивное поведение: известные факты и новые гипотезы. Акушерство и гинекология: новости, мнения, обучения. 2018; 3: 15-20. [Arkhipova M.P., Khamoshina M.B. Reproductive behavior: known facts and new hypotheses // Obstetrics and Gynecology. News. Opinions. Learning. (in Russian)].
  2. Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 729: Importance of social determinants of health and cultural awareness in the delivery of reproductive health care. Obstet. Gynecol. 2018; 131(1): e43-8.
  3. Радзинский В.Е., Хамошина М.Б., Маклецова С.А. Время понятной контрацепции. Оптимизация врачебного выбора гормональной контрацепции как путь сохранения здоровья женщин на популяционном уровне : информационный бюллетень. М.: Медиабюро Статус презенс; 2016. 24 с. [Radzinsky V.E., Khamoshina M.B., Makletsova S.A. Time to understand contraception. Optimization of the medical choice of hormonal contraception as a way to preserve the health of women at the population level: newsletter // StatusPraesens journal editors. Media Bureau Status of a business, 2016. 24 p. (in Russian)].
  4. Радзинский В.Е., Аганезова Н.В., Дубровина С.О., Карахалис Л.Ю., Кулешов В.М., Мальцева Л.И., Межевитинова Е.А., Минкина Г.Н., Обоскалова Т.А., Подзолкова Н.М., Пустотина О.А., Спиридонова Н.В., Тарасова М.А., Тихомиров А.Л. Расширение доступа к гормональной контрацепции в России: прагматические решения. Резолюция совета экспертов. РМЖ. Мать и дитя. 2017; 25(26): 1946-9. [Radzinsky V. et al. Resolution Expert Board. Increasing access to hormonal contraception in Russia: pragmatic solutions //RMJ. Mother and child. 2017. No. 26. P. 1946-1949. (in Russian)].
  5. Blode H., Klipping C., Richard F., Trummer D., Rohde B., Diefenbach K. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception. 2012; 85(2): 177-84.
  6. Daly L.E., Kirke P.N., Molloy A., Weir D.G., Scott J.M. Folate levels and neural tube defects: implications for prevention. JAMA. 1995; 274(21): 1698-702.
  7. Eichholzer M., Tönz O., Zimmermann R. Folic acid: a public-health challenge. Lancet. 2006; 367(9519): 1352-61.
  8. Wald N.J., Law M.R., Morris J.K., Wald D.S. Quantifying the effect of folic acid. Lancet. 2001; 358(9298): 2069-73.
  9. Schroecksnadel K., Frick B., Fiegl M., Winkler C., Denz H.A., Fuchs D. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin. Chem. Lab. Med. 2007; 45(1): 47-53.
  10. Peng Y., Dong B., Wang Z. Serum folate concentrations and all-cause , cardiovascular disease and cancer mortality : A cohort study based on 1999–2010 National Health and Nutrition Examination Survey (NHANES). Int. J. Cardiol. 2016; 219: 136-42.
  11. Castaño P.M., Aydemir A., Sampson-Landers C., Lynen R. The folate status of reproductive-aged women in a randomised trial of a folate-fortified oral contraceptive: dietary and blood assessments. Public Health Nutr. 2014; 17(6): 1375-83.
  12. Northrup H., Volcik K.A. Spina bifida and other neural tube defects. Curr. Probl. Pediatr. 2000; 30(10): 313-32.
  13. Esfahani S.T., Cogger E.A., Caudill M.A. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J. Am. Diet. Assoc. 2003; 103(2): 200-7.
  14. Cordero A.M., Crider K.S., Rogers L.M., Cannon M.J., Berry R.J. Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines. MMWR. Morb. Mortal. Wkly Rep. 2015; 64(15): 421-3.
  15. Регистрационное удостоверение Джес Плюс. [Electronic resource] // 2017. P. ЛП 001189-111111. URL: (accessed: 11.03.2019).
  16. Rivera R., Guerra A. Management of acne in women over 25 years of age. Actas Dermosifiliogr. 2009; 100(1): 33-7.
  17. Hernádi L., Marr J., Trummer D., De Leo V., Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception. 2009; 80(1): 18-24.
  18. Chaiyasit N., Taneepanichskul S. A study of cycle control, side effects and client’s satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone–N24/4 regimen. J. Med. Assoc. Thai. 2010; 93(5):517-22.
  19. Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3): 191-8.
  20. Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone. Clin. Drug Investig. 2009; 29(2): 73-8.
  21. Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006; 5(11): 949-60.

Received 15.03.2019

Accepted 20.03.2019

About the Authors

Khamoshina, Marina B., MD, professor, Department of Obstetrics and Gynecology, Medical Institute, Peoples’ Friendship University of Russia.
117198, Russia, Moscow, Miklukho-Maklaya str. 6.

For citation: Khamoshina M.B. Results of the observational study EVA PLUS: Use of combined oral contraceptives with f olate in real clinical practice in Russia. Akusherstvo i Ginekologiya/Obstetrics and Gynecology.2019; (3): 114-20. (in Russian)

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.